Myriad Genetics Current Deferred Revenue Over Time
| MYGN Stock | USD 15.71 0.22 1.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Myriad Genetics Performance and Myriad Genetics Correlation. Myriad |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Myriad Genetics and related stocks such as Guardant Health, Caredx Inc, and Castle Biosciences Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 3.1 M | 16.1 M | 12.3 M | 8.6 M | 11.3 M | 17.4 M | 18 M | 12.2 M |
| CDNA | 813 K | 813 K | 813 K | 80 K | 505 K | 142 K | 42 K | 39 K | 39 K | 3.7 M | 20.5 M | 55.3 M | 5.3 M | 4.7 M | 8.4 M |
| CSTL | 9.7 K | 9.7 K | 9.7 K | 9.7 K | 9.7 K | 9.7 K | 9.7 K | 9.7 K | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 7.6 M | 8 M |
| SHC | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 3.6 M | 6.1 M | 8.7 M | 12.1 M | 13.5 M | 8.9 M |
| NEOG | 1.9 M | 2 M | 2 M | 2 M | 2 M | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | 3.4 M | 5.5 M | 4.6 M | 4.6 M | 3.3 M |
| RDNT | 5.4 M | 2.1 M | 1.3 M | 1.3 M | 2 M | 1.6 M | 1.5 M | 2.6 M | 2.4 M | 1.3 M | 39.3 M | 10.7 M | 4 M | 4.6 M | 6.7 M |
| NTRA | 970 K | 970 K | 970 K | 970 K | 112 K | 144 K | 574 K | 1.4 M | 4.1 M | 56 M | 50.1 M | 7.4 M | 10.8 M | 9.1 M | 14.1 M |
| MEDP | 58.1 M | 58.1 M | 58.1 M | 58.1 M | 58.1 M | 51.1 M | 65.7 M | 73.8 M | 147.9 M | 192.4 M | 255.7 M | 344.6 M | 462.7 M | 559.9 M | 587.9 M |
| PSNL | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 24.7 M | 42.9 M | 36 M | 21 M | 4 M | 1.3 M | 3.3 M | 3.1 M |
| QGEN | 15.9 M | 32.9 M | 27.3 M | 50.6 M | 49.2 M | 49.8 M | 44.6 M | 49.4 M | 45.4 M | 48.5 M | 57.1 M | 63.4 M | 69 M | 66.4 M | 63.1 M |
| ACRS | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 5.9 M | 10.1 M | 19.4 M | 22.4 M | 11.9 M |
| EXAS | 4.5 M | 4.1 M | 6.1 M | 6.1 M | 14 M | 22.3 M | 28.1 M | 49.1 M | 105.2 M | 193.3 M | 233.6 M | 398.6 M | 3.1 M | 76.9 M | 84.2 M |
| ILMN | 10 M | 63.6 M | 69.6 M | 64.4 M | 95.6 M | 117.6 M | 141.1 M | 150 M | 175 M | 167 M | 186 M | 234 M | 245 M | 252 M | 264.6 M |
| TWST | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 7.6 M | 7.6 M | 16.4 M | 18.8 M | 28.8 M | 3.5 M | 3.5 M | 2.1 M | 2 M |
Myriad Genetics and related stocks such as Guardant Health, Caredx Inc, and Castle Biosciences Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Myriad Genetics | MYGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Utah; U.S.A |
| Exchange | NASDAQ Exchange |
USD 15.71
Check out Myriad Genetics Performance and Myriad Genetics Correlation. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Myriad Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.